Cargando…
Botulinum toxin–induced blepharoptosis: Anatomy, etiology, prevention, and therapeutic options
BACKGROUND: Botulinum toxin A (BoNT‐A) has grown tremendously in aesthetic dermatology since 2002 when the United States Food and Drug Administration (FDA) first approved its use for treating moderate‐to‐severe glabellar lines. Blepharoptosis, due to local spread of toxin, is a reported side effect...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290925/ https://www.ncbi.nlm.nih.gov/pubmed/34378298 http://dx.doi.org/10.1111/jocd.14361 |